| P2093 | author name string | Massimo Iavarone | |
| | Marcelo Silva | |
| | Federico Piñero | |
| P2860 | cites work | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. | Q46274669 |
| | Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial | Q47376936 |
| | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 |
| | SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 |
| | AASLD guidelines for the treatment of hepatocellular carcinoma | Q56172239 |
| | Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial | Q56355520 |
| | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 |
| | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study | Q56384328 |
| | Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy | Q58811082 |
| | Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib | Q64134542 |
| | EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma | Q88301343 |
| | Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial | Q88310077 |
| | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Q89012806 |
| | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q91147767 |
| | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial | Q91879742 |
| | Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation | Q92309511 |
| | Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis | Q92323560 |
| | Insights into the success and failure of systemic therapy for hepatocellular carcinoma | Q92353495 |
| | Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial | Q92830327 |
| | A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. | Q33368982 |
| | Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study | Q33374394 |
| | Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. | Q33375908 |
| | Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. | Q33376718 |
| | Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study | Q33379271 |
| | Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study | Q33403393 |
| | Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 |
| | A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. | Q33419633 |
| | First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study | Q33420684 |
| | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 |
| | Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study | Q33441170 |
| | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | Q33747394 |
| | Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma | Q34566598 |
| | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 |
| | Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 |
| | Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma | Q37710134 |
| | Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial | Q37809940 |
| | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. | Q38062681 |
| | Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma | Q38778021 |
| | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 |
| | Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. | Q38993647 |
| | Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). | Q39109076 |
| | Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study | Q39548624 |
| | Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies | Q40131537 |
| | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 |
| | Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. | Q41489415 |
| | The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. | Q41923187 |
| | Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study | Q42606277 |
| | Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia | Q42615624 |
| | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. | Q42989841 |
| | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 |
| | Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design | Q43950860 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 16 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| | immunological antineoplastic agent | Q50429626 |
| P304 | page(s) | 1888-1900 | |
| P577 | publication date | 2020-04-01 | |
| | 2020-04-28 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors | |
| P478 | volume | 26 | |